Oregon Board of Pharmacy
Statement Adopted by the Board
October 2023
Statement on Access to Buprenorphine for Patients Requiring Medication-Assisted Treatment for Opioid Use Disorder
Adopted October 2023
The Oregon Board of Pharmacy is committed to protecting the health, safety and welfare of all Oregonians. Addressing the opioid epidemic is a critical public health priority, and ensuring access to evidence-based treatments, such as medication-assisted treatment (MAT), is essential to combating this crisis. Buprenorphine, a proven and effective medication, plays a significant role in supporting individuals with opioid use disorder (OUD) on their path to recovery. Recognizing the importance of accessible and convenient care, the Board of Pharmacy encourages all wholesale distributors and pharmacies to maintain adequate supplies of buprenorphine to facilitate access for patents seeking treatment of OUD.
Opioid use disorder is a complex and challenging health issue affecting countless individuals across the US and the State of Oregon. Medication-assisted treatment has demonstrated efficacy in reducing the harms associated with opioid misuse, including overdose and infectious disease transmission, while promoting sustained recovery and improved quality of life. Buprenorphine, a partial opioid agonist, has been shown to be safe and effective in managing withdrawal symptoms and cravings, allowing individuals to regain stability and function within their communities.
Community pharmacies play a vital role in healthcare delivery and are well-positioned to partner in the effective management of OUD by making buprenorphine available to patients seeking treatment. Pharmacies, particularly those in rural and underserved communities, are often the first point of contact for individuals seeking healthcare services, making them a critical and accessible resource for patients requiring MAT. Pharmacists are important members of the healthcare team providing services that help support patients' physical, psychological, and social needs throughout their recovery.
The Board of Pharmacy supports minimizing barriers to accessing buprenorphine and other essential medications for those seeking treatment for OUD. Wholesale distributors and pharmacies are encouraged to make buprenorphine products available to the extent possible to support patients being treated for OUD.
|
